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Background: Several diagnostic definitions are available for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis
(CFS/ME) that varies significantly in their symptom criteria. This pilot study was conducted to determine whether
simple biological and clinical measures differed between CFS/ME patients meeting the 1994 Centres for Disease
Control and Prevention (CDC) criteria, the International Consensus Criteria (ICC), as well as healthy controls.
Methods: A total of 45 CFS/ME patients and 30 healthy controls from the South East Queensland region of
Australia provided a blood sample, reported on their current symptoms, as well as aspects of their physical and
social health using the Short-Form Health Survey (SF-36), and the World Health Organisation Disability Adjustment
Schedule 2.0 (WHO DAS 2.0). Differences were examined using independent sample t-testing.
Results: Patients fulfilling the ICC definition reported significantly lower scores (p < 0.05) for physical functioning,
physical role, bodily pain, and social functioning than those that only fulfilled the 1994 CDC definition. ICC patients
reported significantly greater (p < 0.05) disability across all domains of the WHO DAS 2.0.
Conclusions: These preliminary findings suggest that the ICC identifies a distinct subgroup found within patients
complying with the 1994 CDC definition, with more severe impairment to their physical and social functioning.
Keywords: Chronic fatigue syndrome, Disability, Myalgic encephalomyelitis, Health-related quality of lifeIntroduction
The term Chronic Fatigue Syndrome/Myalgic Encephalo-
myelitis (CFS/ME) first appeared in the literature in 1988
when the Centres for Disease Control and Prevention
(CDC) described an illness of debilitating fatigue accompan-
ied by a various combination of symptoms [1]. Throughout
the 1950s to 1980s however, outbreaks of CFS/ME-like ill-
ness have been reported as Bornholm disease [2], Iceland
disease [3], the Royal Free Hospital epidemic [4], as well as
Chronic Epstein Barr Virus Syndrome [5]. In recent de-
cades, several formal case definitions have been released for
CFS/ME [6-12], and each differ significantly in the symp-
toms they emphasise, as well as their exclusion criteria [13].* Correspondence: samantha.johnston3@griffithuni.edu.au
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unless otherwise stated.The most common definition is the 1994 CDC, which
requires the presence of debilitating fatigue of 6 months,
and at least four of eight, mostly flu-like symptoms [8].
It was primarily developed for the selection of adult cases
in research however, concerns have been raised on its se-
lection of widely heterogeneous patients [14,15].
A more stringent definition, known as the Canadian
Consensus Criteria was released in 2003 [7], primarily for
diagnosis in clinical settings. Criteria included core symp-
toms found in the 1994 CDC such as debilitating fatigue
for 6 months, post-exertional malaise, sleep dysfunction,
and pain, as well as symptoms relating to dysfunction of
the neurological, autonomic, neuroendocrine, and im-
mune systems. Its application in research however, sug-
gests that patients fulfilling the Canadian definition have
more severe impairment to their physical functioning and
cognition than 1994 CDC defined patients [16,17].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the International Consensus Criteria (ICC) [6]. The
most significant change in the ICC definition was the
removal of criteria for fatigue, with a revised emphasis
on fatigability, referred to as post-exertional neuroim-
mune exhaustion (PENE). Accompanying symptoms are
then categorised into three pathophysiologies relating to
dysfunction of the neurological system, immune and
gastro-intestinal system, and deregulation of energy me-
tabolism and ion transportation. This latest definition has
yet to be applied regularly in CFS/ME research.
A major criticism of the 1994 CDC definition is that it
has remained the most common criteria for CFS/ME
due to consensus [18]. The ICC was proposed based on
collective empirical findings on dysfunction found in
CFS/ME patients fulfilling broader definitions of the ill-
ness [19-29]. These findings, however, may be more
prominent in a more homogenous sample. The potential
of the ICC to identify a distinct subgroup of CFS/ME
may, therefore, enhance the opportunity of discovering a
unique biological marker for the illness. The aim of this
study was to compare patients fulfilling the 1994 CDC
definition, the ICC definition, and healthy controls. It
examined whether differences could be found in stand-
ard blood tests for screening of the disease that are rec-
ommended for differential diagnosis of CFS/ME [30-32].
It also examined impairments using the Short Form 36
Item Health Survey (SF-36) [33], and the World Health
Organisation’s Disability Adjustment Schedule 2.0 (WHO
DAS 2.0) [34]. These findings provide the first preliminary
data available regarding standard biological and clinical
measures in CFS/ME patients complying with the 1994
CDC and ICC definitions.
Method
The study involved a blood sample and cross-sectional
survey of participants self-reporting a current diagnosis
of CFS/ME, and healthy controls, aged 18 to 64 years.
Participants were part of a larger study examining im-
munological markers and were recruited from support
networks in the South East Queensland region. Written
consent was obtained from all eligible participants be-
fore collecting a blood sample to measure their full
blood count (FBC), erythrocyte sedimentation rate (ESR)
and electrolytes. Participants were also required to
complete a hard copy of self-reporting measures. This
included the National Centre for Neuroimmunology and
Emerging Diseases (NCNED) CFS/ME questionnaire de-
veloped by the authors. Within the questionnaire was a
checklist consisting of a total of 53 symptoms derived
from the 1994 CDC [8], Canadian [7] and ICC defini-
tions [6]. Participants first had to indicate how many
months they had been experiencing chronic, debilitating
fatigue. Participants then selected symptoms from thechecklist that had been present and disruptive during
the past 30 days. They were also asked to list their
current medications and medical history including psy-
chiatric conditions.
To be confirmed as a CFS/ME patient, current symp-
toms had to comply. To meet with the 1994 CDC defin-
ition, participants had to experience a debilitating fatigue
for at least 6 months and four or more of the following
symptoms: post-exertional malaise, difficulties with short
term memory or concentration, unrefreshing sleep, sore
throat, muscle pain, joint pain, headaches, and tender
lymph nodes. According to the Canadian definition, pa-
tients had to experience debilitating fatigue for at least
6 months, post-exertional malaise, unrefreshed sleep, and
problems with pain (muscle, joint, and/or headache). Fur-
ther, patients had to indicate at least two neurocognitive
symptoms, and at least one symptom from two of the
remaining categories of autonomic, neuroendocrine, and
immune manifestations from the checklist. To comply
with the ICC definition, patients had to meet all 5 symp-
toms relating to PENE, neurological impairments (at least
one symptom from three subcategories); immune, gastro-
intestinal, and genitourinary impairments (at least one
symptom from three subcategories); and energy metabol-
ism, ion transportation impairments (one symptom).
Those reporting physical and psychiatric conditions
that could potentially explain their symptoms were ex-
cluded from the study. Secondary screening of reported
medications was also conducted, and patients on hor-
mone therapy were also excluded. Healthy controls were
defined as having no reported signs of illness. Partici-
pants also completed self-reporting measures of their
health according to the SF-36 [33] and the WHO DAS
2.0 [34] surveys. The SF-36 has previously been examined
in patients fulfilling the 1994 CDC [8] and Canadian
criteria [35,36]. It investigates eight subscales according
to: physical functioning, role limitations due to physical
problems, bodily pain, general perception of physical
health, vitality, social functioning, role imitations due
to emotional problems, and general perception of men-
tal health [33]. Scoring ranged between 0 and 100, with
lower values representing greater impairment. The
WHO DAS 2.0 assesses patients according to its frame-
work for the International Classification for Function-
ing, Disability and Health (ICF), but has yet to be
applied in CFS/ME patients [37]. It consists of six do-
mains to assess difficulties in health relating to commu-
nication, mobility, self-care, interpersonal relations, life
activities, and participation in society, over the past
30 days. Scoring also ranged between 0 and 100, with
higher values indicating greater impairment.It was ob-
served that all patients that complied with the ICC defin-
ition also fulfilled the 1994 CDC definition. Based on this,
the study used three independent groups for analysis:
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tients that fulfilled the ICC definition, and healthy con-
trols. Five cases in the 1994 CDC group were found to
also comply with the Canadian definition, but not the ICC
definition. Due to low statistical power of this sample
alone, these cases remained in the 1994 CDC group for
analysis. SPSS v.22 was used to compare mean scores on
the SF-36 and WHO DAS 2.0 between 1994 CDC and
ICC patient groups, and between all patients and healthy
controls, using independent sample t-testing. Categorical
variables were analysed using chi-squared test when ap-
propriate. Using G*Power 3.1.9.2, a sample size of at least
18 per group, at a power of 0.8 was deemed acceptable to
observe a large effect size in this pilot study. Results were
considered significant at the p < 0.05 level and highly sig-
nificant at the p < 0.001 level. The study was approved by
the Griffith University Human Research Ethics Committee.
Results
Of 45 self-reporting CFS/ME patients recruited into the
study, 4 did not comply with any CFS/ME definitions
and were excluded from analysis. Of the 41 patients in-
cluded, 19 reported symptoms that only fulfilled the
1994 CDC definition, and 22 fulfilled the ICC definition.
The 30 healthy controls recruited remained in the study
as they indicated no signs of illness. Basic characteristicsTable 1 Characteristics of 1994 CDC patients, ICC patients, an
Parameters 1994 CDC patients (n = 19)
Age, mean (SD) 50.7 (7.4)
Gender (% female) 68%
Illness duration (years), mean (SD) 18.9 (13.6)
Haemoglobin (g/L) mean (SD) 134.9 (13.6)
White cell count (x109/L) mean (SD) 6.1 (1.5)
Platelets (×109/L) mean (SD) 247.9 (66.8)
Haematocrit mean (SD) 0.41 (0.04)
Red cell count (×1012/L) mean (SD) 4.45 (0.4)
Mean corpuscular volume (×109/L) 91.8 (3.6)
Neutrophils (×109/L) mean (SD) 3.75 (1.3)
Lymphocytes (×109/L) mean (SD) 1.83 (0.4)
Monocytes (×x109/L) mean (SD) 0.30 (0.1)
Eosionophils (×109/L) mean (SD) 0.17 (0.1)
Basophils (×109/L) mean (SD) 0.03 (0.03)
ESR (mm/Hr) mean (SD) 15.5 (11.2)
Sodium (mmol/L) mean (SD) 138.6 (1.3)
Potassium (mmol/L) mean (SD) 4.0 (0.3)
Chloride (mmol/L) mean (SD) 104.1 (2.0)
Bicarbonate (mmol/L) mean (SD) 26.7 (2.1)
Anions (mmol/L) mean (SD) 7.9 (1.3)
aSignificant difference between 1994 CDC and International patient groups.
bSignificant difference between all patient and healthy control groups.and standard blood results for each study group are pre-
sented in Table 1. The age distribution was similar be-
tween the three study groups, but a significantly higher
number of females (p < 0.05) was found among ICC pa-
tients. The mean duration of illness of approximately
19 years was the same between the two patient groups.
Significant differences (p < 0.05) were detected between
all patients and healthy control groups in Haemoglobin,
Haematocrit, and Red Cell Count with higher levels
found in healthy controls. Patients also exhibited signifi-
cantly higher Erythrocyte Sedimentation Rates (ESR) in
comparison to healthy controls. No difference however,
was found between 1994 CDC and ICC patients across
these markers.
The results for the SF-36 are presented in Table 2. CFS/
ME patients complying with either of the study criteria re-
ported significantly lower scores for all eight SF-36 sub-
scales (p < 0.001, except p < 0.05 for mental health), when
compared to healthy controls. Among the patients, those
that fulfilled the ICC definition reported significantly
lower scores (p < 0.05) for physical functioning, physical
role, bodily pain, and social functioning than those that
only fulfilled the 1994 CDC criteria.
Table 3 presents the results of the WHO DAS 2.0. The
1994 CDC patients reported significantly higher scores
(p < 0.05) for all disability domains compared to healthyd healthy controls
ICC patients (n = 22) Healthy controls (n = 30) Sig.
49.3 (13.2) 49.7 (10.9)
95% 66% <0.05a
19.0 (10.2) n/a
132.9 (11.9) 140.7 (12.6) <0.05b
6.1 (1.9) 6.0 (1.5)
276.7 (68.5) 235.5 (48.2)
0.40 (0.03) 0.43 (0.03) <0.05b
4.40 (0.4) 4.65 (0.43) <0.05b
91.6 (2.9) 92.0 (2.5)
3.48 (1.6) 3.81 (1.28)
2.04 (0.8) 1.72 (0.43)
0.34 (0.1) 0.32 (0.12)
0.15 (0.1) 0.15 (0.11)
0.03 (0.03) 0.03 (0.02)
15.7 (13.8) 10.2 (8.4) <0.05b
130.8 (30.0) 138.2 (1.8)
9.3 (23.2) 4.0 (0.3)
99.6 (17.5) 103.6 (2.5)
24.7 (5.3) 26.5 (2.6)
8.6 (2.5) 8.3 (1.7)
Table 2 SF-36 Scores of 1994 CDC defined patients, ICC defined patients, and healthy controls






1994 CDC vs ICC 1994 CDC vs controls ICC vs controls
Physical functioning 58.7 (20.9) 35.0 (23.3) 96.1 (8.4) p = 0.002 p = 0.000 p = 0.000
Physical role 21.1 (29.2) 1.25 (5.6) 96.4 (14.8) p = 0.005 p = 0.000 p = 0.000
Bodily pain 62.9 (24.6) 44.8 (26.2) 94.3 (9.6) P = 0.030 p = 0.000 p = 0.000
General health 36.8 (21.3) 31.3 (21.5) 82.5 (9.6) p > 0.05 p = 0.000 p = 0.000
Vitality 26.6 (15.4) 19.2 (18.0) 67.6 (15.9) p > 0.05 p = 0.000 p = 0.000
Emotional role 52.6 (46.2) 47.4 (48.8) 92.0 (21.2) p > 0.05 p = 0.000 p = 0.000
Social functioning 26.8 (21.4) 19.2 (15.6) 94.9 (10.6) p = 0.002 p = 0.000 p = 0.000
Mental health 66.2 (21.2) 62.5 (22.9) 79.1 (14.6) p > 0.05 p = 0.018 p = 0.003
Lower scores indicate greater impairment.
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fered significantly across all domains. Significant differ-
ences were also found in domains of cognition, mobility,
self-care (p < 0.001), as well as life activities, and partici-
pation (p < 0.05) between 1994 CDC and ICC patients.
Discussion
This is the first study to examine CFS/ME patients that
fulfil the ICC definition in an Australian sample. As all
ICC defined patients complied with 1994 CDC defin-
ition, this study supports findings that ICC defined pa-
tients may be classified as a subgroup found within the
broader category of CFS/ME [38]. Though broad criteria
may be particularly useful for the identification of poten-
tial cases among small samples, it could inadvertently
select those that do not have the illness [39]. The symp-
toms of chronic fatigue, post-exertional malaise, short-
term memory and concentration problems reported in
1994 CDC defined CFS/ME cases are found to overlap
with cases of depression [40]. The Canadian definition
however, has been shown to effectively differentiate be-
tween those with CFS/ME and depression [17]. In an-
other study, 96% of self-reporting cases of CFS/ME were
found to comply with the 1994 CDC, compared to 77% of
that complied with the Canadian definition [36]. These
findings are consistent with the findings of this study,
which is based on a similar method of recruitment and
case ascertainment as, 91% of self-reporting cases fulfilledTable 3 WHO DAS 2.0 scores in 1994 CDC patients, ICC patien






Cognition 22.6 (16.2) 43.5 (17.6) 4.0 (5.6)
Mobility 27.1 (17.6) 48.2 (15.5) 1.4 (3.0)
Self-care 14.0 (9.6) 22.2 (16.5) 16.5 (0.7)
Getting along 15.6 (15.2) 44.2 (22.7) 22.7 (5.5)
Life activities 39.9 (25.9) 63.1 (23.8) 23.8 (6.3)
Participation 38.2 (20.4) 53.9 (16.5) 16.5 (3.6)
Higher scores indicate greater impairment.the 1994 CDC definition, 60% also fulfilled the Canadian
definition, and 49% fulfilled the 1994 CDC, Canadian and
ICC definitions.
An important consideration is a consistent method of
applying criteria [41]. Reliance on self-reporting versus
evaluation of cases by a physician can be a particular
source of variability in reported cases of CFS/ME [42].
The symptom checklist used to verify the study criteria
is limited to self-reporting of symptoms present during
the past 30 days, and reporting of existing physical and
psychiatric diagnoses. Self-reporting however, can be a
useful tool for the initial evaluation of cases of research.
Like the Canadian definition, the ICC definition was de-
vised for clinical applications. Accordingly, the Inter-
national Primer was published in 2012 [31], to aid
clinicians in their evaluation of symptoms according to
the ICC definition. The availability of this tool could
contribute to the selection of homogenous patient sets
in research settings and help exclude other causes of ill-
ness. The current primer however, does lack specifica-
tions on how to apply the definition in a research
setting. This includes quantifiable measures on the se-
verity and frequency of symptoms, in order to be consid-
ered significant in CFS/ME and its operationalization is
discussed further by Johnston et al. [41].
As part of recruitment however, this study screened
patients for reported medical history of chronic condi-
tions such as heart disease, diabetes, and primaryts, and healthy controls
1994 CDC vs ICC 1994 CDC vs controls ICC vs controls
p = .000 p = 0.000 p = 0.000
p = .000 p = 0.000 p = 0.000
p = .000 p > 0.05 p = 0.000
p = .000 p = 0.007 p = 0.000
p = .010 p = 0.000 p = 0.000
p = .011 p = 0.000 p = 0.000
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tests as part of routine screening of disease. While all
CFS/ME patients were found to have different results
from controls in some parameters, no difference was
found between the 1994 CDC and ICC patient groups. If
the ICC definition identifies a subgroup with a less het-
erogeneous clinical presentation, important differences
may be found in more specific biological markers than
the ones examined in this study. While basic haemato-
logical abnormalities have not been previously reported
in CFS/ME in relation to FBC, ESR, CRP and electro-
lytes, immunological abnormalities have been increas-
ingly documented in cases of CFS/ME. Subsequently,
salient differences have been detected in immunological
parameters between 1994 CDC and ICC patient sub-
groups. In particular, significant differences in human
neutraphil antigen [43].
The SF-36 survey that was used to evaluate the study
groups is widely recognised as a valid and reliable tool
for assessment of physical and social functioning in
chronic illnesses [21], and has previously demonstrated
impairment in 1994 CDC cases of CFS/ME [35,44,45]. It
has also been used to contrast between patients fulfilling
the 1994 CDC and Canadian definitions [36]. The com-
parison between 1994 CDC and ICC defined patients
has been made in a US sample [38]. ICC defined patients
reported significantly greater impairment in their phys-
ical functioning, bodily pain, physical role, as well as so-
cial functioning, which is consistent with the results
from the Australian sample of this study. The WHO
DAS 2.0 was further found to support the findings from
the SF-36. Hence, there is evidence to suggest that inclu-
sion of more symptoms in the ICC definition may select
a significantly more impaired group.
The 1994 CDC definition for CFS/ME can represent
an illness that ranges from mild impairment in daily ac-
tivities, to severe cases where patients are bedridden and
unable to care for themselves. For many chronic ill-
nesses, the most severe cases often present themselves
to primary or secondary care and mild cases often go
unreported. The characteristics of CFS/ME can be quite
the opposite, as the most debilitating cases can leave pa-
tients housebound or bedridden, and often overlooked
by clinicians and researchers alike. The use of broad cri-
teria with symptoms that overlap with other conditions
can also make cardinal features of CFS/ME difficult to
identify.
The current study suggests that the ICC definition
may identify a more severe subgroup found within trad-
itional CFS/ME and this may be consistent across sam-
ples in different geographic locations. The I994 CDC
definition is limited to a nominal list of symptoms that
may only capture the basic characteristics of the illness.
As the ICC definition introduces a spectrum of symptomsaffecting the neurological, immune and metabolic systems,
it is expected that patients experiencing these further
manifestations be more debilitated.
Limitations in this study include the application of the
ICC definition as further research and consistency is re-
quired on the operationalization of the criteria that is
not currently found in the primer. This study relied on
whether patients had experienced any of the symptoms
within the past 30 days. This time period is consistent
with the time period measured in the SF-36 and WHO
DAS 2.0. However, introducing thresholds for severity
and frequency may provide further insight on the impact
of this illness. It was also found that the majority of
those that also fulfilled the ICC definition were female.
To investigate whether females tended to report greater
symptom severity than males in this subgroup, further
comparison needs to be made in a larger sample size. A
larger sample would also allow for further analysis of
critical symptoms. This could contribute to more accur-
ate and homogenous patient sets for further research on
the aetiology and underlying pathomechanism of the
illness.
The ICC definition has suggested that this subgroup
should be referred to exclusively as Myalgic Encephalo-
myelitis (ME) patients. This proposal however, remains
controversial as the term implies inflammation of the
central nervous system that is not necessarily exhibited
in all cases that fulfil the criteria. The term ME alone,
may be viewed as pathogen-related initiation associated
with onset as seen in bacterial, viral or parasitic infection
and resultant inflammation of the nervous system. How-
ever use of the term in this context may result in mis-
leading assignation of the syndrome directly and solely
to an infectious agent. This has been seen previously
during the XMRV expedition [46-51]. Alternatively the
identification of this illness as due to immune dysfunc-
tion following infection or other initiating event repre-
sents a paradigm in closer fit with observable clinical
signs and laboratory findings. Ongoing discoveries in im-
mune dysfunction are likely to harmonise with more ac-
curate case definitions over time.
Conclusions
The preliminary findings of this study suggest that the
ICC definition identifies a group of patients (generally
females) that reported significantly greater disability,
poorer social functioning, and ‘cognitive’ difficulties in
comparison to the 1994 CDC definition. Though based
on a small sample, these findings in an Australian sam-
ple are highly consistent with those previously reported
in a cohort in the USA. This study included further
comparison of standard blood tests but found no differ-
ence between the two patient groups. Further studies on
the potential of the ICC definition to identify a unique
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physical state aligns with biological abnormalities will be
of benefit for examining whether more specific bio-
logical markers are present in this illness.
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